This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-15 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
By the early modern period, Neo-Latin had become the lingua franca of science, medicine, legal discourse, theology, and education in Europe. Over time, the use of Latin continued where international communication with specialist audiences was paramount. Later, where some of the discourse moved to French, English or German, translations into Latin would allow texts to cross language boundaries, while authors in countries with much smaller language populations or less known languages would tend to continue to compose in Latin. Latin's dominance over medicine began to change in the late seventeenth century, as philosophers and others began to write in their native language first, afterwards translating into Latin for international audiences. In the early part of the 1700s, Latin was still making a significant contribution to academic publishing, but was no longer dominant. Examples of modern medical dictionaries include Mosby's Dictionary of Medicine, Nursing & Health Professions, Stedman's, Taber's, and Dorland's.
Individual variation within any racial group spans over 7 cm (3 inches) in some datasets, a range that is 15 to 30 times greater than the alleged average differences between racial groups, which typically measure less than 0.5 cm (0.2 inches) in clinician-measured studies. Factually race is therefore a poor predictor of any individual's penis size, and reported racial averages do not account for the substantial overlap between group distributions.
Only two divisions (43rd and 53rd), two armoured brigades, and a parachute brigade were to remain allocated for NATO and the defence of Western Europe; the other eight divisions were placed on a lower establishment for home defence only. The territorial units of the Royal Armoured Corps were also reduced in number to nine armoured regiments and eleven reconnaissance regiments. This was effected by the amalgamation of pairs of regiments, and the conversion of four RAC units to an infantry role. The new parachute brigade group become the 44th Independent Parachute Brigade Group. British forces contracted dramatically as the end of conscription in 1960 came in sight as announced in the 1957 Defence White Paper. On 20 July 1960, a reorganisation of the TA was announced in the House of Commons. The territorials were to be reduced from 266 fighting units to 195. There was to be a reduction of 46 regiments of the Royal Artillery, 18 battalions of infantry, 12 regiments of the Royal Engineers and two regiments of the Royal Corps of Signals. The reductions were carried out in 1961, mainly by amalgamating units. Thus, on 1 May 1961, the TA divisional headquarters were merged with regular army districts, which were matched with Civil Defence Regions to aid mobilisation for war. The Army Reserve Act of April 1962 made provision for a new TA Emergency Reserve (TAER), within existing TA units, who could be called out without Royal Proclamation as individuals to reinforce regular units around the world, for up to six months in every twelve.
Sources: en.wikipedia.org
== Detection technique == Helium is used as a tracer because it penetrates small leaks rapidly. Helium also has the properties of being non-toxic, chemically inert and present in the atmosphere only in minute quantities (<6 ppm). Typically a helium leak detector will be used to measure leaks in the range of 10−5 to 10−12 Pa·m3·s−1. When a mass spectrometer is used to sample the leaking helium leaks can be detected up to 10−14 Pa·m3·s−1. A flow of 10−5 Pa·m3·s−1 is about 0.006 ml per minute at standard conditions for temperature and pressure (STP). A flow of 10−13 Pa·m3·s−1 is about 0.003 ml per century at STP.
== Pharmacology == CVnCoV is an mRNA vaccine that encodes the full-length, pre-fusion stabilized coronavirus spike protein, and activates the immune system against it. CVnCoV technology does not interact with the human genome. CVnCoV uses unmodified RNA, unlike the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine, which both use nucleoside-modified RNA.
=== Bacteria === Many common culturable laboratory strains are deep-frozen to preserve genetically and phenotypically stable, long-term stocks. Sub-culturing and prolonged refrigerated samples may lead to loss of plasmid(s) or mutations. Common final glycerol percentages are 15, 20, and 25. From a fresh culture plate, one single colony of interest is chosen and liquid culture is made. From the liquid culture, the medium is directly mixed with an equal amount of glycerol; the colony should be checked for any defects like mutations. All antibiotics should be washed from the culture before long-term storage. Methods vary, but mixing can be done gently by inversion or rapidly by vortex and cooling can vary by either placing the cryotube directly at −50 to −95 °C, shock-freezing in liquid nitrogen or gradually cooling and then storing at −80 °C or cooler (liquid nitrogen or liquid nitrogen vapor). Recovery of bacteria can also vary, namely, if beads are stored within the tube then the few beads can be used to plate or the frozen stock can be scraped with a loop and then plated, however, since only little stock is needed the entire tube should never be completely thawed and repeated freeze-thaw should be avoided. 100% recovery is not feasible regardless of methodology.
After his release from jail, Colonel Rhodes immediately joined his brother Cecil and the British South Africa Company in the Second Matabele War taking place just north of the Transvaal in Matabeleland. Cecil Rhodes was forced to resign as Prime Minister of Cape Colony in 1896 due to his apparent involvement in planning and assisting in the raid; he also, along with Alfred Beit, resigned as a director of the British South Africa Company. Jameson's raid had depleted Matabeleland of many of its troops and left the whole territory vulnerable. Seizing on this weakness, and a discontent with the British South Africa Company, the Ndebele revolted during March 1896 in what is now celebrated in Zimbabwe as the First War of Independence, the First Chimurenga, but it is better known to most of the world as the Second Matabele War. The Shona joined them soon thereafter. Hundreds of European settlers were killed within the first few weeks of the revolt and many more would die over the next year and a half. With few troops to support them, the settlers had to quickly build a laager in the centre of Bulawayo on their own. Against over 50,000 Ndebele held up in their stronghold of the Matobo Hills the settlers mounted patrols under such people as Burnham, Baden-Powell, and Selous. It would not be until October 1897 that the Ndebele and Shona would finally lay down their arms.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.